Just a few days after NexImmune bumped up its credentials with the hiring of Gilead Sciences and Kite Pharma alum Robert Knight, M.D., the T-cell biotech is now gunning for an $86 million IPO.
The startup wants the cash to boost its work on immunotherapy, with its platform designed to employ the body’s own T cells to generate a potent and durable immune response that mimics natural biology.
“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases,” the Maryland biotech said in its Securities and Exchange Commission filing.
Read the full article at FierceBiotech
Latest posts by BioBuzz Media (see all)
- NeoImmuneTech Appoints Byung Ha Lee, Ph.D., as Chief Scientific Officer - March 2, 2021
- Germantown’s QIAGEN launches QIAcube Connect MDx platform for automated sample processing in diagnostic labs - March 2, 2021
- The Children’s National Hospital Rare Disease Institute and Takeda Partner to Standardize Care for Patients With Rare Diseases - March 1, 2021
- Novel Microdevices Joins Baltimore’s LaunchPort™ Medtech Venture Center - February 26, 2021
- Altimmune Commences Enrollment In Phase 1 Clinical Trial Of AdCOVID™ — A Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate - February 25, 2021